Sign in
Taking peoplePhase 2

Preliminary Effectiveness of Hybrid Individual and Group MDMA-assisted Therapy for War-related PTSD

Key facts

Who runs it
Guy Schusheim
Where
Israel1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
60 people, planned
Started
1 Jun 2023
Expected to end
1 Jul 2028
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • methylenedioxymethamphetamine
Record updated
15 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 35 criteriaShow less

Who can take part

  • Experienced war-related trauma
  • Fluent in speaking and reading Hebrew
  • Able to swallow capsules
  • Willing to have study visits, including MDMA experimental sessions and non-drug psychotherapy sessions, audio- and/or video-recorded as specified by the protocol
  • Able to identify a relative, spouse, close friend, or other support person who can be contacted by the investigators if the participant becomes suicidal or cannot be reached
  • Agrees to inform the investigators within 48 hours of relevant medical conditions or procedures
  • Agrees to comply with study requirements, including fasting and medication restrictions before experimental sessions, refraining from participation in other interventional clinical trials during the study, remaining overnight at the study site after each experimental session, arranging accompanied transportation after discharge, and complying with study medication, psychotherapy, and assessment procedures
  • At screening, meets DSM-5 criteria for current PTSD of the protocol-specified minimum duration
  • At screening, has at least moderate PTSD symptom severity, defined as a CAPS-5 total score of 28 or greater

Who cannot take part

  • Use of Ecstasy or material represented as containing MDMA more than 10 times during the previous 10 years, or any such use within 6 months before the first experimental session
  • Previous participation in a MAPS-sponsored MDMA clinical trial
  • Electroconvulsive therapy within 12 weeks before enrollment
  • Active illicit-drug or prescription-drug substance use disorder, other than caffeine or nicotine use disorder, within 12 months before enrollment, as defined by the protocol
  • Requirement for ongoing treatment with a psychiatric medication that cannot be discontinued or is not permitted under the protocol, except as specified in the concomitant-medication provisions
  • History of clinically significant arrhythmia within 12 months before screening, other than premature atrial contractions or occasional premature ventricular contractions in the absence of ischemic heart disease
  • Ketamine-assisted therapy or ketamine use within 12 weeks before enrollment
  • Any current medical, psychiatric, psychosocial, or other condition that, in the judgment of the investigator or study physician, could interfere with safe or effective participation
  • Known sensitivity or allergy to MDMA or another study intervention that, in the judgment of the sponsor-investigator or study clinician, contraindicates participation
  • Current or lifetime primary psychotic disorder
  • Current eating disorder involving active purging, as assessed by the MINI and clinical interview
  • Current major depressive disorder with psychotic features, as assessed by the MINI
  • Current alcohol or substance use disorder judged by the investigators, therapy team, or study physician to represent a safety concern
  • Current personality disorder meeting the protocol-specified exclusion criteria
  • Medical condition for which exposure to a sympathomimetic drug or associated increases in blood pressure or heart rate would pose an unacceptable risk
  • Uncontrolled hypertension, defined according to the protocol as blood pressure of 140/90 mmHg or higher on three separate occasions
  • History of ventricular arrhythmia other than premature ventricular contractions in the absence of ischemic heart disease
  • Wolff-Parkinson-White syndrome or another accessory conduction pathway that has not been successfully treated by ablation
  • Symptomatic liver disease or clinically significant liver-enzyme elevations
  • History of hyponatremia or hyperthermia
  • Baseline QTc prolongation greater than 450 ms in males or greater than 460 ms in females, corrected using Fridericia's formula
  • Additional risk factors for torsade de pointes, including heart failure, hypokalemia, or a family history of long-QT syndrome
  • Requirement for concomitant medications that prolong the QT/QTc interval during experimental sessions
  • Unable to provide adequate informed consent
  • Current serious suicide risk
  • Body weight below 48 kg

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The overall objective of this study is to use standard clinical measures to explore the safety and preliminary effectiveness of open-label MDMA-assisted therapy with a flexible dose of methylenedioxymethamphetaminel, in participants with war-related Post traumatic Stress Disorder, in a hybrid individual and group treatment protocol.

Read full original descriptionShow less

The overall safety objective is to assess the severity, incidence, and frequency of AEs, AEs of Special Interest (AESIs), and Serious Adverse Events (SAEs), concomitant medication use, suicidal ideation and behavior and vital signs .

The 2 groups in the trial

  • MDMA-assisted therapyTreatment being tested

    Participants receive an approximately 18-week MDMA-assisted therapy intervention combining individual and group treatment. The intervention includes three individual preparatory sessions; two individual MDMA-assisted sessions, each followed by three individual integration sessions; two group preparatory sessions; one group MDMA-assisted session followed by three group integration sessions; and a final individual integration and termination session.

    Treatment: methylenedioxymethamphetamine

  • Treatment as usual controlNo study treatment, for comparison

    The nonrandomized treatment-as-usual (TAU) comparison cohort will comprise participants with war-related PTSD recruited concurrently from the same target population. Participants will receive no protocol-directed MDMA-assisted intervention and will continue any routine psychiatric, psychological, or other clinical care available to them outside the study. Eligibility criteria for the TAU cohort are less restrictive than those applied to the MDMA-assisted therapy arm. Study assessments will be conducted at baseline and approximately 3.5 months later, approximating the baseline-to-post-treatment interval in the MDMA-assisted therapy arm. Participants will receive US$500 for study participation.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Record updated
15 October 2026